Detalle Publicación

Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a collaborative initiative comparing intranodal and intradermal cell administration in two phase I clinical trials

Autores: Willekens, B.; Presas-Rodriguez, S. ; Mansilla, M.; Derdelinckx, J. ; Lee, W. P.; Nijs, G.; Laere, M.; Wens, I.; Cras, P.; Parizel, P. M.; Hecke, W. ; Ribbens, A.; Adams, G.; Couttenye, M.; Navarro-Barriuso, J.; Teniente-Serra, A.; Quirant-Sanchez, B.; Verheij, H. ; Kip, A.; López Díaz de Cerio, Ascensión; Inoges Sancho, Susana Inmaculada; Prosper Cardoso, Felipe; Gross, C. C.; Wiendl, H.; Ham, S.; Brinke, A.; Barriocanal, A.; Massuet-Vilamajo, A.; Hens, N.; Berneman, Z. ; Martinez-Caceres, E.; Cools, N.; Ramo-Tello, C.
Título de la revista: MULTIPLE SCLEROSIS
ISSN: 1352-4585
Volumen: 24
Número: 2_suppl: P1202
Páginas: 530 - 737
Fecha de publicación: 2018
Resumen:
Objectives: To assess the clinical use of tolDC in a well-defined population of MS patients in two single-center clinical trials, comparing two ways of tolDC administration, namely intradermal (i.d.) (MS-tolDC, Antwerp) and intranodal (i.n.) (TOLERVIT-MS, Badalona). Aims: To demonstrate safety and feasibility of therapeutic use of tolDC in MS patients.
DOI: https://doi.org/https://doi.org/10.1177/1352458518798591
Impacto:
Google Scholar